New potential therapies for the treatment of antiphospholipid syndrome

Bibliography

• Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983;287(6399):1088-89
   PubMed Web of Science ®Google Scholar
• Vander A, Sherman J, Luciano D. Human physiology. 6th edition. USA: McGraw-Hill; 1994
   Google Scholar
• Leung L. Overview of hemostasis. Available from: http://www.uptodate.com/online/content/topic.do?topicKey=coagulat/9319&selectedTitle=1∼150&source=search_result. [August 27, 2008]
   Google Scholar
• Clemetson KJ. Platelet GPIb-V-IX complex. Thromb Haemost 1997;78:266-70
   PubMedGoogle Scholar
• Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992;267:11300-06
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-49
   PubMed Web of Science ®Google Scholar
• Tracy PB, Eide LL, Bowie EJ, et al. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982;60:59-63
   PubMed Web of Science ®Google Scholar
• Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 1985;260:2119-24
   PubMed Web of Science ®Google Scholar
• Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982;257:7944-7
   PubMed Web of Science ®Google Scholar
• Esmon CT. The protein C pathway. Chest 2003;124(3 Suppl):S26-32
   PubMed Web of Science ®Google Scholar
• Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994;8:37-55
   PubMedGoogle Scholar
• Bajaj MS, Birktoft JJ, Steer SA, et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-72
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27
   PubMed Web of Science ®Google Scholar
• Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
   PubMed Web of Science ®Google Scholar
• Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002;90:29-37
   PubMed Web of Science ®Google Scholar
• Shibata S, Harpel PC, Gharavi A, et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994;83:2532-40
   PubMed Web of Science ®Google Scholar
• Lellouche F, Martinuzzo M, Said P, et al. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991;78:2894-9
   PubMed Web of Science ®Google Scholar
• Khamasha M, Hughes G. Oxford textbook of rheumatology. 3rd edition. Oxford: Oxford University Press;2004
   Google Scholar
• Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992;32:196-209
   PubMedGoogle Scholar
• Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007;56:2382-91
   PubMed Web of Science ®Google Scholar
• Wawrzynska L, Tomkowski WZ, Przedlacki J, et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003;33:64-7
   PubMed Web of Science ®Google Scholar
• Erre GL, Pardini S, Faedda R, et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008;17:50-5
   PubMed Web of Science ®Google Scholar
• Ioannou Y, Lambrianides A, Cambridge G, et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008;67:425-6
   PubMed Web of Science ®Google Scholar
• Bauer A. Therapeutic use of fondaparinux. Available from: http://www.uptodate.com/online/content/topic.do?topicKey=coagulat/14857&selectedTitle=3∼21&source=search_result. [August 5, 2008]
   Google Scholar
• Leung L. New anticoagulants. Available from: http://www.uptodate.com/online/content/topic.do?topicKey=coagulat/8976&selectedTitle=1∼150&source= search_result. [October 16, 2008]
   Google Scholar
• Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008;99:819-29
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91
   PubMed Web of Science ®Google Scholar
• Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin 2008;26:169-87, v-vi
   PubMed Web of Science ®Google Scholar
• Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-42
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-11
   PubMed Web of Science ®Google Scholar
• Gurewich V. Ximelagatran – promises and concerns. JAMA 2005;293:736-9
   PubMed Web of Science ®Google Scholar
• Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998;91:4197-205
   PubMed Web of Science ®Google Scholar
• Van Amsterdam RJ. Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis. AU2003205664; 2008
   Google Scholar
• Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371(9609):315-21
   PubMed Web of Science ®Google Scholar
• Yang W, Gao X, Wang B. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 2003;23:346-68
   PubMed Web of Science ®Google Scholar
• Madge DJ. Parental formulations comprising boronic acid species for selective thrombin inhibition. EP1695711; 2006
   Google Scholar
• Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004;24:1015-22
   PubMed Web of Science ®Google Scholar
• Pierangeli SS, Vega-Ostertag ME, Gonzalez EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med 2007;9(30):1-15
   PubMedGoogle Scholar
• Jiao J, Luepschen L, Nieves E, et al. Pharmaceutically active compounds and methods of use thereof. EP1882695A2; 2008
   Google Scholar
• Girardi G, Salmon JE. Treatment for antiphospholipid-syndrome-related-pregnancy complications. AU2006338560; 2007
   Google Scholar
• Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007;110:2423-31
   PubMed Web of Science ®Google Scholar
• Ganong W. Review of medical physiology. 17th edition. USA: Appleton and Lange; 1995
   Google Scholar
• Dorsch D. Derivatives of phenoxy-n-′4-(isothiazolindin-1,1-dioxid-2yl)phenyl!-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors. US7199133; 2007
   Google Scholar
• Wang S, Blench T, Marlin F, et al. Heterocyclic compounds and their use in the treatment of cardiovascular disease. WO2007096362; 2007
   Google Scholar
• Mjalli A, Andrews R, Guo X, et al. Aryl and heteroaryl compounds and methods to modulate coagulation. US2006276518; 2006
   Google Scholar
• Tassies D, Espinosa G, Munoz-Rodriguez FJ, et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000;43:2349-58
   PubMedGoogle Scholar
• Commons TJ, Woodworth RP. Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1 (PAI-I) modulators useful in the treatment of thrombosis and cardiovascular diseases. WO2006023865 2006
   Google Scholar
• Inghardt T, Johansson A, Svensson A. New mandelic acid derivatives and their use as thrombin inhibitors. WO03018551; 2006
   Google Scholar
• Weitz J, Hirsh J. Heparin compositions that inhibit clot associated coagulation factors. US2008119438; 2008
   Google Scholar
• Khosla SK, Baumhauer JF. Dietary and viscosupplementation in ankle arthritis. Foot Ankle Clin 2008;13:353-361
   PubMedGoogle Scholar
• Saito T, Sakamoto K. Blood flow improvers comprising glucosamine salts or derivatives thereof. TW289452; 2007
   Google Scholar
• Hua J, Suguro S, Ishii Y, et al. Inhibitory Actions of glucosamine on platelet functions. Inflamm Regen 2003;23:164-9
   Google Scholar
• Edgar A, Junien J, Wilkins M. Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate. EP1621200; 2007
   Google Scholar
• Renaud S, Morazain R, Sauvanet JP, et al. Influence of a hypolipemic drug (procetofene) on platelet functions and lipid composition in type II B hyperlipoproteinemia. Haemostasis 1979;8:82-95
   PubMedGoogle Scholar
• Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50
   PubMed Web of Science ®Google Scholar
• Okada Y. Use of astaxanthin or esters thereof as a phosphodiesterase inhibitor. EP1733721; 2006
   Google Scholar
• Mawaheb M, Ahmed M. Treatment of inflammatory, cancer, and thrombosis disorders. US20080113951; 2008
   Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
   PubMed Web of Science ®Google Scholar
• Larkins N. Preparation for the relief of disease. US20060127508; 2006
   Google Scholar
• Sim DS, Dilks JR, Flaumenhaft R. Platelets possess and require an active protein palmitoylation pathway for agonist-mediated activation and in vivo thrombus formation. Arterioscler Thromb Vasc Biol 2007;27:1478-85
   PubMed Web of Science ®Google Scholar
• Flaumenhaft R. Compositions and methods for inhibiting platelet activation and thrombosis. US2007060605; 2007
   Google Scholar
• Jenkins S, Liversidge G. Nanoparticulate clopidrogrel and aspirin combination formulations. CA2611741; 2007
   Google Scholar
• Cerrito F, Lazzaro MP, Gaudio E, et al. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993;53:209-15
   PubMed Web of Science ®Google Scholar
• Gullapalli R, Martin M, Morgan M, et al. Pharmaceutical compositions of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto. CA2621152; 2007
   Google Scholar
• Anzalone S. Use of amtolmetin guacyl for the production of a drug for counteracting blood platelet aggregation. EP1709963; 2006
   Google Scholar
• Boyer J, Olins G, Yerxa B, et al. Composition and method for inhibiting platelet aggregation. WO0216381; 2006
   Google Scholar
• Diz-Kucukkaya R, Inanc M, Afshar-Kharghan V, et al. P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome. Ann Rheum Dis 2007;66:1378-80
   PubMed Web of Science ®Google Scholar
• Mcever R, Alvarez R, Kawar Z. Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases. WO2008069999; 2008
   Google Scholar
• Light D, Mclean K. Novel tissue factor targeted antibodies as anticoagulants. NZ536243; 2006
   Google Scholar
• Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005;106:2340-6
   PubMed Web of Science ®Google Scholar
• Habash L, Jones C. Nitroxides for use in treating or preventing immunological diseases. WO2006084198; 2006
   Google Scholar
• Delgado Alves J, Mason LJ, Ames PR, et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxf) 2005;44:1238-44
   PubMed Web of Science ®Google Scholar
• Strobel H, Wohlfart P, Zoller G, et al. Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals. EP1741709; 2007
   Google Scholar
• Zoller G, Strobel H, Will D, et al. Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals. WO2008037381; 2008
   Google Scholar